Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease:: a double blind, placebo controlled, randomised trial

被引:58
|
作者
Wu, JCY [1 ]
Chan, FKL [1 ]
Ching, JYL [1 ]
Leung, WK [1 ]
Hui, Y [1 ]
Leong, R [1 ]
Chung, SCS [1 ]
Sung, JJY [1 ]
机构
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China
关键词
D O I
10.1136/gut.2003.012641
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The role of Helicobacter pylori eradication in the management of gastro-oesophageal reflux disease (GORD) is controversial. We hypothesised that H pylori eradication leads to worsened control of reflux disease. Methods: Consecutive patients with weekly reflux symptoms were prospectively recruited for endoscopy and symptom evaluation. Patients were enrolled if they had H pylori infection and required long term acid suppressants. Eligible patients were randomly assigned to omeprazole triple therapy (HpE group) or omeprazole with placebo antibiotics (Hp+ group) for one week. Omeprazole 20 mg daily was given for eight weeks for healing of oesophagitis and symptom relief. This was followed by a maintenance dose of 10 mg daily for up to 12 months. The primary study end point was the probability of treatment failure within 12 months, which was defined as either incomplete resolution of symptoms or oesophagitis at the initial treatment phase, or relapse of symptoms and oesophagitis during the maintenance phase. Predictors of treatment failure were determined by Cox's proportional hazards model. Results: A total of 236 GORD patients were screened and 113 (47.9%) were positive for H pylori; 104 (92%) patients were included in the intention to treat analysis (53 in the HpE group and 51 in the Hp+ group). Thirty one patients (30%) had erosive oesophagitis at baseline. H pylori was eradicated in 98% of the HpE group and in 3.9% of the Hp+ group. Overall, 15 patients (28.3%) in the HpE group and eight patients (15.7%) in the Hp+ group had treatment failure. The 12 month probability of treatment failure was 43.2% (95% confidence interval (CI) 29.9-56.5%) in the HpE group and 21.1% (95% CI 9.9-32.3%) in the Hp+ group (log rank test, p = 0.043). In the Cox proportional hazards model, after adjustment for the covariates age, sex, erosive oesophagitis, hiatus hernia, degree of gastritis, and severity of symptoms at baseline, H pylori eradication was the only predictor of treatment failure (adjusted hazard ratio 2.47 (95% CI 1.05-5.85)). Conclusion: H pylori eradication leads to more resilient GORD.
引用
收藏
页码:174 / 179
页数:6
相关论文
共 50 条
  • [31] Role of Helicobacter pylori in carditis, metaplasia and gastro-oesophageal reflux disease
    Bowrey, DJ
    Clark, GWB
    Stockdale, E
    Williams, GT
    Carey, PD
    BRITISH JOURNAL OF SURGERY, 1998, 85 (11) : 1574 - 1575
  • [32] Helicobacter pylori infection is associated with milder gastro-oesophageal reflux disease
    Wu, JCY
    Sung, JJY
    Chan, FKL
    Ching, JYL
    Ng, ACW
    Go, MYY
    Wong, SKH
    Ng, EKW
    Chung, SCS
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (04) : 427 - 432
  • [33] Review article:: gastro-oesophageal reflux disease and Helicobacter pylori infection
    Vakil, NB
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 : 47 - 51
  • [34] The role of cagA Helicobacter pylori strains in gastro-oesophageal reflux disease
    Pereira-Lima, JC
    Marques, DL
    Pereira-Lima, LF
    Hornos, AP
    Rota, C
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2004, 16 (07) : 643 - 647
  • [35] SLEEP POSITIONAL THERAPY FOR NOCTURNAL GASTRO-OESOPHAGEAL REFLUX: A DOUBLE-BLIND, RANDOMISED, SHAM-CONTROLLED TRIAL
    Schuitenmaker, Jeroen M.
    Kuipers, Thijs
    Nijhuis, Renske Anne Berndien Oude
    Schijven, Marlies
    Smout, Andreas J.
    Fockens, Paul
    Bredenoord, Arjan
    GASTROENTEROLOGY, 2022, 162 (07) : S1 - S1
  • [36] Symptomatic gastro-oesophageal reflux disease:: double blind controlled study of intermittent treatment with omeprazole or ranitidine
    Bardhan, KD
    Müller-Lissner, S
    Bigard, MA
    Porro, GB
    Ponce, J
    Hosie, J
    Scott, M
    Weir, DG
    Gillon, KRW
    Peacock, RA
    Fulton, C
    BRITISH MEDICAL JOURNAL, 1999, 318 (7182): : 502 - +
  • [37] Helicobacter pylori and gastro-oesophageal reflux disease -: Information on underlying pathology is not given
    Cammarota, G
    Gasbarrini, GB
    BMJ-BRITISH MEDICAL JOURNAL, 2004, 329 (7462): : 402 - 402
  • [38] Eradication of Helicobacter pylori infection might have a positive impact on subpopulations with endoscopic gastro-oesophageal reflux disease
    Kountouras, Jannis
    Zavos, Christos
    Polyzos, Stergios A.
    Katsinelos, Panagiotis
    Stergiopoulos, Christos
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 26 (01) : 123 - 123
  • [39] Helicobacter pylori and gastro-oesophageal reflux disease -: clinical implications and management.
    O'Connor, HJ
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 (02) : 117 - 127
  • [40] Symposium:: Helicobacter pylori and clinical risks -: focus on gastro-oesophageal reflux disease
    Malfertheiner, P
    O'Connor, HJ
    Genta, RM
    Unge, P
    Axon, ATR
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 : 1 - 10